Wegovy HD (7.2 mg) is now FDA-approved with 20.7% average weight loss. Learn about results, effects, availability, and how it compares to Zepbound.
FDA warned 30 telehealth companies over GLP-1 marketing claims. Learn what changed, why compounding is not going away, and what to look for.
64% of Americans say GLP-1 drugs hurt body positivity. Here's what research says about body image, Ozempic face, and making health decisions.
New research links semaglutide to 42% fewer psychiatric hospitalizations. See what studies show about GLP-1 medications, depression, and anxiety.
Eli Lilly claims B12 in compounded GLP-1s creates an impurity. We break down what the data shows, what's missing, and whether you should worry.
Medicare covers Wegovy and Zepbound for $50/month starting July 2026. Learn who qualifies, what it costs, and how to prepare for the GLP-1 Bridge.
Protect your muscle mass on a GLP-1 medication with these 7 beginner bodyweight exercises you can do at home in 10 minutes.
GLP-1 microdosing for longevity is trending. We break down the science, what microdosing really means, and whether the evidence supports it.
A Stanford study of 5,000+ GLP-1 users found that small behavior changes make a real difference. Here are the 8 microsteps and how to start.
GLP-1 medications like Ozempic and Wegovy can reduce appetite and lead to nutritional gaps. Here is what the research says and how to stay protected.
The FDA warned Novo Nordisk for not reporting deaths and serious side effects tied to its GLP-1 medications. Here is what happened.
Products marketed as "natural GLP-1s" and peptide supplements are everywhere. Here is what the science says and how to protect yourself.
